Skip to Content
U.S. National Institutes of Health
Last Updated: 03/05/10

Support for Clinical and Translational Research

The Diagnostics Evaluation Branch of the Cancer Diagnosis Program is sponsoring two initiatives to support early phases of translational research.

PA-03-003, Exploratory Studies in Cancer Detection, Diagnosis and Prognosis, invites applications for exploratory/developmental (R21) grants to begin the investigation of a new diagnostic strategy.

PAR-03-098, Phased Application Awards in Cancer Prognosis and Prediction, offers phased application (R21/R33 or R33) awards to support subsequent steps in the clinical evaluation of promising diagnostic strategies. PAR-03-098 offers the option of applying for a phased application award, in which expedited transition from the exploratory (R21) phase to the application (R33) phase relies upon the achievement of negotiated, peer-reviewed milestones. PAR-03-099 is a parallel announcement for small business (SBIR/STTR) grant applications.

See more: The Funding Opportunities page describes additional NCI initiatives for clinical correlative studies.